Recursion Pharmaceuticals (RXRX) Cash from Investing Activities (2020 - 2026)

Recursion Pharmaceuticals (RXRX) has 7 years of Cash from Investing Activities data on file, last reported at -$338000.0 in Q1 2026.

• Quarterly Cash from Investing Activities rose 95.35% year-over-year to -$338000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$9.9 million (down 103.83% YoY) and the FY2025 annual result came in at -$16.9 million, down 106.49% from the prior year.
• Cash from Investing Activities climbed to -$338000.0 in Q1 2026, from -$1.2 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $275.5 million in Q4 2024 to a low of -$8.0 million in Q4 2022.
• A 5-year average of $25.1 million and a median of -$2.5 million in 2023 frame the typical range for Cash from Investing Activities.
• The widest YoY moves for Cash from Investing Activities: up 11171.38% in 2024, down 1214.7% in 2024.
• Tracing RXRX's Cash from Investing Activities over 5 years: stood at -$8.0 million in 2022, then surged by 68.82% to -$2.5 million in 2023, then soared by 11171.38% to $275.5 million in 2024, then sank by 100.45% to -$1.2 million in 2025, then soared by 72.83% to -$338000.0 in 2026.
• The last three Cash from Investing Activities figures came in at -$338000.0 (Q1 2026), -$1.2 million (Q4 2025), and -$2.5 million (Q3 2025), per Business Quant data.